Stratification Tools for Disease-Modifying Trials in Prodromal Synucleinopathy.

Dario ArnaldiPietro MattioliFrancesco FamàNicola GirtlerAndrea BrugnoloMatteo PardiniAndrea DonniaquioFederico MassaBeatrice OrsoStefano RaffaMatteo BaucknehtSilvia MorbelliFlavio Nobili

Published in: Movement disorders : official journal of the Movement Disorder Society (2021)

The TMT-B seems to be a cost-effective and efficient first-line screening tool, to be used to select patients that deserve DAT-SPECT as second-line screening tool for disease-modifying clinical trials. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Keyphrases

clinical trial
end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
peritoneal dialysis
parkinson disease
systematic review
study protocol